Advantage Trust Company’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1M Hold
865
– – 0.35% 25
2026
Q2
$1.04M Buy
865
+200
+30% +$204K 0.37% 24
2026
Q1
$612K Hold
665
– – 0.27% 24
2025
Q4
$715K Sell
665
-211
-24% -$202K 0.32% 22
2025
Q3
$668K Hold
876
– – 0.3% 27
2025
Q2
$683K Buy
876
+186
+27% +$145K 0.34% 26
2025
Q1
$570K Hold
690
– – 0.35% 26
2024
Q4
$533K Hold
690
– – 0.31% 26
2024
Q3
$611K Hold
690
– – 0.42% 22
2024
Q2
$625K Sell
690
-14
-2% -$11.2K 0.45% 19
2024
Q1
$548K Hold
704
– – 0.4% 23
2023
Q4
$410K Hold
704
– – 0.32% 28

Other funds holding LLY

Advantage Trust Company's LLY Position: Q3 2026 in Review

Advantage Trust Company held its Eli Lilly (LLY) position steady in Q3 2026 at 865 shares worth $1M. The position accounts for 0.35% of the portfolio, ranked #25.

Advantage Trust Company first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.04M in Q2 2026. 4,624 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Advantage Trust Company held 865 shares of Eli Lilly worth $1M as of Q3 2026.
  • Advantage Trust Company left its Eli Lilly share count unchanged in Q3 2026.
  • Eli Lilly made up 0.35% of Advantage Trust Company's portfolio in Q3 2026, its #25 holding.
  • Advantage Trust Company first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • Advantage Trust Company's Eli Lilly position peaked at $1.04M in Q2 2026.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Advantage Trust Company's 13F filing for Q3 2026, filed 19 Oct 2026.